Who are Ga-PSMA-11's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Technetium Tc99m Sestamibi, Fludeoxyglucose F 18 (FDG), Ga-68-DOTATOC, Radium-223, Copper Cu 64 Dotatate, strontium-89.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ga-psma-11.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Ga-PSMA-11 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ga-PSMA-11 (Ga-PSMA-11) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Radiopharmaceutical; PET imaging agent. Area: Oncology.

phase 3 Radiopharmaceutical; PET imaging agent PSMA (prostate-specific membrane antigen) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Ga-PSMA-11 (Ga-PSMA-11) — University of Colorado, Denver. Ga-PSMA-11 is a gallium-68 labeled imaging agent that binds to prostate-specific membrane antigen (PSMA) on prostate cancer cells to enable PET imaging detection.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Ga-PSMA-11 TARGET	Ga-PSMA-11	University of Colorado, Denver	phase 3	Radiopharmaceutical; PET imaging agent	PSMA (prostate-specific membrane antigen)
Technetium Tc99m Sestamibi	Technetium Tc99m Sestamibi	Lantheus Medical Imaging	marketed	Radiopharmaceutical imaging agent	Mitochondrial membrane potential
Fludeoxyglucose F 18 (FDG)	Fludeoxyglucose F 18 (FDG)	Teva Branded Pharmaceutical Products R&D, Inc.	marketed	Radiopharmaceutical; PET imaging agent	Glucose transporter (GLUT1); hexokinase
Ga-68-DOTATOC	Ga-68-DOTATOC	Weill Medical College of Cornell University	marketed	Radiopharmaceutical	Somatostatin receptors (SSTRs) on neuroendocrine tumor cells
Radium-223	radium-223	Pfizer	marketed	Radiopharmaceutical	Bone cells
Copper Cu 64 Dotatate	Copper Cu 64 Dotatate	Vanderbilt-Ingram Cancer Center	marketed	Radiopharmaceutical; somatostatin receptor agonist imaging agent	Somatostatin receptor 2 (SSTR2)
strontium-89	strontium-89	Alberta Health services	marketed	Radiopharmaceutical; bone-seeking radioisotope	Hydroxyapatite in bone matrix; osteoblast uptake

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Radiopharmaceutical; PET imaging agent class)

Clarity Pharmaceuticals Ltd · 1 drug in this class
Radiomedix, Inc. · 1 drug in this class
Teva Branded Pharmaceutical Products R&D, Inc. · 1 drug in this class
UMC Utrecht · 1 drug in this class
University of Colorado, Denver · 1 drug in this class
University of Saskatchewan · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ga-PSMA-11 — Competitive Intelligence Brief. https://druglandscape.com/ci/ga-psma-11. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing